Comparison of Detection of Antibodies with Yeast Lysate Antigens Prepared from Two Isolates of Blastomyces dermatitidis by Two Different Methods: Sensitivity and Specificity Evaluations

Tiffany R. Allison, Gene M. Scalarone

Department of Biological Sciences, Idaho State University, Pocatello, USA.

DOI: 10.4236/ojmm.2012.24022                

Abstract

Blastomycosis, a systemic fungal disease, caused by the dimorphic fungus Blastomyces dermatitidis, has continually presented clinicians with concerns with regard to laboratory diagnosis and prevention. For years researchers have strived to develop antigens with a high degree of sensitivity and specificity. The purpose of this study was to gain a bet- ter understanding of how two novel yeast lysate antigens, prepared from two B. dermatitidis isolates by different meth- ods, would be able to detect antibody responses in immunized rabbits in a specific and sensitive manner. The en- zyme-linked immunosorbent assay (ELISA) was used to evaluate antibody in serum specimens with yeast lysate re- agents prepared after allowing yeast cells to lyse for 1 or 7 days. The results indicated that reactivity was greater with the day 7 antigens, with both the B5896 and 597 B. dermatitidis isolates, when compared to the day 1 antigens; in con- trast the day 1 preparations exhibited less cross reactivity when assayed against anti-Histoplasma capsulatum serum specimens.

Keywords

Isoelectric Focusing; ELISA; Blastomycosis; Lysate Antigen; Antibody Detection

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	M. A. Pfaller and D. J. Diekema, “Epidemiology of Invasive Mycoses in North America,” Critical Reviews in Microbiology, Vol. 36, No. 1, 2010, pp. 1-53. doi:10.3109/10408410903241444
[2]	A. F. Di Salvo, “Blastomycosis,” In: Topley and Wilson’s Microbiology and Microbial Infections, 9th Edition, Arnold Publishers, London, 1998, pp. 337-355.
[3]	M. A. De Groote, R. Bjerke, H. Smith and L. V. Rhodes III, “Expanding Epidemiology of Blastomycosis: Clinical Features and Investigation of 2 Cases in Colorado,” Clinical Infectious Diseases, Vol. 30, No. 3, 2000, pp. 582-584. doi:10.1086/313717
[4]	R. W. Bradsher, “Clinical Features of Blastomycosis,” Seminars in Respiratory Infections, Vol. 12, No. 3, 1997, pp. 229-234.
[5]	R. W. Bradsher, S. W. Chapman and P. G. Pappas, “Blastomycosis,” Infectious Disease Clinics of North America, Vol. 17, No. 1, 2003, pp. 21-40. doi:10.1016/S0891-5520(02)00038-7
[6]	J. A. Smith and C. A. Kauffman, “Pulmonary Fungal Infections,” Respirology, Vol. 17, No. 6, 2012, pp. 913-926. doi:10.1111/j.1440-1843.2012.02150.x
[7]	J.A. Smith and C. A. Kauffman, “Blastomycosis,” Proceedings of the American Thoracic Society, Vol. 7, No. 3, 2010, pp. 173-180.
[8]	J. R. Bariola and K. S. Vyas, “Pulmonary Blastomycosis,” Seminars in Respiratory Critical Care Medicine, Vol. 32, No. 6, 2011, pp. 745-753. doi:10.1055/s-0031-1295722
[9]	J. A. McKinnell and P. G. Pappas, “Blastomycosis: New Insights into Diagnosis, Prevention, and Treatment,” Clinical Chest Medicine, Vol. 30, No. 2, 2009, pp. 227239. doi:10.1016/j.ccm.2009.02.003
[10]	M. Saccente and G. L. Woods, “Clinical and Laboratory Update on Blastomycosis,” Clinical Microbiology Reviews, Vol. 23, No. 2, 2010, pp. 367-381. doi:10.1038/nrmicro1537
[11]	J. E. Cutler, G. S. Deepe Jr. and B. S. Klein, “Advances in Combating Fungal Diseases: Vaccines on the Threshold,” Nature Review of Microbiology, Vol. 5, No. 1, 2007, pp. 13-28.
[12]	K. S. Vyas, J. R. Bariola and R. W. Bradsher, “Advances in the Serodiagnosis of Blastomycosis,” Current Fungal Infection Reports, Vol. 2, No. 4, 2008, pp. 227-231. doi:10.1007/s12281-008-0033-z
[13]	B. S. Klein and J. M. Jones, “Isolation, Purification and Radiolabeling of a Novel 120-kD Surface Protein on Blastomyces dermatitidis Yeasts to Detect Antibody in Infected Patients,” Journal of Clinical Investigation, Vol. 85, No. 1, 1990, pp. 152-161. doi:10.1172/JCI114406
[14]	P. Connolly, C. A. Hage, J. R. Bariola, E. Bensadoun, M. Rodgers, R. W. Bradsher and J. J. Wheat, “Blastomyces dermatitidis Antigen Detection by Quantitative Enzyme Immunoassay,” Clinical Vaccine Immunology, Vol. 19, No. 1, 2012, pp. 53-56. doi:10.1128/CVI.05248-11
[15]	C. A. Hage, T. E. Davis, L. Egan, M. Parker, D. Fuller, A. M. LeMonte, D. Durkin, P. Connelly, L. J. Wheat, D. Blue-Hindy and K. A. Knox, “Diagnosis of Pulmonary Histoplasmosis and Blastomycosis by Detection of Antigen in Bronchoalveolar Lavage Fluid Using an Improved Second-Generation Enzyme-Linked Immunoassay,” Respiratory Medicine, Vol. 101, No. 1, 2007, pp. 43-47. doi:10.1016/j.rmed.2006.04.017
[16]	B. S. Klein, R. A. Squires, J. K. Lloyd, D. R. Ruge and A. M. Legendre, “Canine Antibody Response to Blastomyces dermatitidis WI-1 Antigen,” American Review of Veterinary Research, Vol. 61, No. 5, 2000, pp. 554-558.
[17]	D. Spector, A. M. Legendre, J. Wheat, D. Bemis, B. Rohrbach, J. Taboada and M. Durkin, “Antigen and Antibody Testing for the Diagnosis of Blastomycosis in Dogs,” Journal of Veterinary Internal Medicine, Vol. 22, No. 4, 2008, pp. 839-843. doi:10.1111/j.1939-1676.2008.0107.x
[18]	J. R. Bariola, C. A. Hage, M. Durkin, E. Bensadoun, P. O. Gubbins, L. J. Wheat and R. W. Bradsher, “Detection of Blastomyces dermatitidis Antigen in Patients with Newly Diagnosed Blastomycosis,” Diagnostic Microbiology and Infectious Diseases, Vol. 69, No. 2, 2011, pp. 187-191. doi:10.1016/j.diagmicrobio.2010.09.015
[19]	S. M. Johnson and G. M. Scalarone, “Preparation and ELISA Evaluation of Blastomyces dermatitidis Yeast Phase Lysate Antigens,” Diagnostic Microbiology and Infectious Diseases, Vol. 11, No. 2, 1988, pp. 81-86. doi:10.1016/0732-8893(88)90076-4
[20]	J. L. Bono, A. M. Legendre and G. M. Scalarone, “Detection of Antibodies and Delayed Hypersensitivity with Rotofor Preparative IEF Fractions of Blastomyces dermatitidis Yeast Phase Lysate Antigens,” Journal of Medical and Veterinary Mycology, Vol. 33, No. 4, 1995, pp. 209214. doi:10.1080/02681219580000441
[21]	M. A. Fisher, J. L. Bono, R. O. Abuodeh, A. M. Legendre and G. M. Scalarone, “Sensitivity and Specificity of an Isoelectric Focusing Fraction of Blastomyces dermatitidis Yeast Lysate Antigen for the Detection of Canine Blastomycosis,” Mycoses, Vol. 38, No. 5-6, 1995, pp. 177-182. doi:10.1111/j.1439-0507.1995.tb00046.x
[22]	R. C. Axtell and G. M. Scalarone, “Serological Differences in three Blastomyces dermatitidis Strains,” Mycoses, Vol. 45, No. 11-12, 2002, pp. 437-442.
[23]	J. F. Shurley, A. M. Legendre and G. M. Scalarone, “Blastomyes dermatitidis Antigen Detectioni in Urine Specimens from Dogs with Blastomycosis Using a Competitive Binding Inhibition ELISA,” Mycopathologia, Vol. 160, No. 2, 2005, pp. 137-142. doi:10.1007/s11046-005-3153-9
[24]	J. F. Shurley and G. M. Scalarone, “Isoelectric Focusing and ELISA Evaluation of a Blastomyces dermatitidis Human Isolate,” Mycopathologia, Vol. 164, No. 2, 2007, pp. 73-76. doi:10.1007/s11046-007-9033-8
[25]	C. M. Sestero and G. M. Scalarone, “Detection of IgG and IgM in Sera from Canines with Blastomycosis Using Eight Blastomyces dermatitidis Yeast Phase Lysate Antigens,” Mycopathologia, Vol. 162, No. 1, 2006, pp. 33-37. doi:10.1007/s11046-006-0028-7
[26]	C. M. Sestero and G. M. Scalarone, “Detection of the Surface Antigens BAD-1 and Alpha-(1,3)-Glucan in Six Different Strains of Blastomyces dermatitidis Using Monoclonal Antibodies,” Journal of Medical and Biological Science, Vol. 1, No. 1, 2006, pp. 1-7.
[27]	W. O. Hatch and G. M. Scalarone, “Comparison of Colorimetric and Chemiluminescent ELISAs for the Detection of Antibodies to Blastomyces dermatitidis,” Journal of Medical and Biological Sciences, Vol. 3, No. 1, 2009, pp. 1-6.
[28]	Minnesota Department of Health, “Minnesota Department of Health Disease Control Newsletter,” Blastomycosis, Vol. 31, No. 4, 2003, pp. 1-6.
[29]	B. S. Klein, J. M. Vergeront, R. J. Weeks, U. N. Kumar, G. Mathai, B. Varkey, L. Kaufman, R. W. Bradsher, J. R. Stoebig and J. P. Davis, “Isolation of Blastomyces dermatitidis in Soil Associated with a Larger Outbreak of Blastomycosis in Wisconsin,” Journal of Infectious Diseases, Vol. 155, No. 2, 1986, pp. 262-268. doi:10.1093/infdis/155.2.262
[30]	H. B. Levine, G. M. Scalarone and S. D. Chaparas, “Preparation of Fungal Antigens and Vaccines: Studies on ‘Coccidioides immitis’ and ‘Histoplasma capsulatum’,” Contributions to Microbiology and Immunology, Vol. 3, 1977, pp. 106-125.
[31]	G. M. Scalarone, H. B. Levine and S. D. Chaparas, “Delayed Hypersensitivity Responses of Experimental Animals to Histoplasmin from the Yeast and Mycelial Phases of Histoplasma capsulatum,” Infection and Immunity, Vol. 21, No. 3, 1978, pp. 705-713.
[32]	H. B. Levine, G. M. Scalarone, G. D. Campbell, R. C. Graybill and S. D. Chaparas, “Histoplasmin-CYL, a Yeast Phase Reagent in Skin Test Studies in Humans,” American Review of Respiratory Diseases, Vol. 119, No. 4, 1979, pp. 629-636.